Daniel J. Landsburg, MD

Hematology
Accepting new patients
Sees patients age 18 and up
Abramson Cancer Center Perelman 4th Floor West
Make an appointmentCall 215-615-5858
Headshot of Daniel J. Landsburg, MD
Penn Medicine Provider

About me

  • Medical Director, Infusion Services, Hospital of the University of Pennsylvania
  • Physician Leader, Oncology Clinical Effectiveness Team
  • Associate Professor of Clinical Medicine (Hematology-Oncology)

My education and training

  • Medical School: Temple University School of Medicine
  • Residency: University of Pennsylvania Health System
  • Fellowship: University of Pennsylvania Health System

Reviews

Average Rating

846 reviews

Comments are submitted by patients and reflect their views and opinions. The comments are not endorsed by and do not necessarily reflect the views of Penn Medicine.

Anonymous
May 2026
wonderful doctor, expert in his field.
Anonymous
May 2026
dr is on time and positive in nature
Anonymous
May 2026
dr. landsburg listens to me when i talk, and his expertise and experience warrant a hearty well-deserved recommendation.
Anonymous
May 2026
quick to answer questions. was very unhurried. friendly demeanor.

Insurance accepted

Please contact the practice and/or the member services department of your insurance company for specific details before receiving services. Providers may participate in some, but not all, products offered by a health plan; providers may also accept plans at some practice locations but not others.

Locations

Penn Medicine hospital privileges

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.
Dr. Landsburg is a Penn Medicine physician.

Qualifications and experience

Treatments and Conditions

Research

Publications

Schneider M, Paruzzo L, Stella F, Noll JH, Ho M, Babatunde V, Ho B, Devi P, Chong EA, Barta SK, Nasta SD, Svoboda J, Carter J, Cook MR, Hossain NM, Thomas CJ, Patel V, de Souza VB, Alkhatib MH, Li Z, Tan M, Michener P, Guruprasad P, Imparato A, Carturan A, Porazzi P, Fraietta JA, Schuster SJ, Maillard I, Ruella M, Landsburg DJ. Naïve CD4(+) T-cells and disease status at CART infusion correlate with clinical outcomes in real-world large B-cell lymphoma patients receiving second-line CAR T therapy , Nat Commun: 2026

Landsburg DJ, Musoke N, Gentile C, Brooks TR, Nasta SD, Barta SK, Carter JS, Chong EA, Svoboda J, Schuster SJ, Thomas CJ, Tomasulo EB, Cook MR, Morrissette JJD, Caimi PF, Hill BT. Prognostic impact of TP53 alterations in cases of newly diagnosed large B-cell lymphoma , Leukemia, 40(3): 2026,694-697

Landsburg DJ, Frigault MJ, Heim M, Foley SR, Hill B, Schofield G, Jacobson CA, Jaglowski S, Locke FL, Ram R, Riedell PA, Shah G, Popplewell LL, Tiwari R, Lim S, Majdan M, Masood A, Pasquini M, Turtle CJ. Real-world outcomes with tisagenlecleucel in aggressive B-cell lymphoma: subgroup analyses from the CIBMTR registry , J Immunother Cancer, 13(2): 2025,e009890

Schneider M, Nasta SD, Barta SK, Chong EA, Svoboda J, Schuster SJ, Landsburg DJ. Analysis of Histologic, Immunohistochemical and Genomic Features of Large B Cell Lymphoma Tumors May Predict Response to Polatuzumab Vedotin Based Therapy in Patients With Relapsed/Refractory Disease , Clin Lymphoma Myeloma Leuk, 25(1): 2025,45-51

Maillie L, Nasta SD, Svoboda J, Barta SK, Chong EA, Garfall AL, Gill SI, Porter DL, Schuster SJ, Catania C, Frey NV, Landsburg DJ. Prolonged Neurologic Symptoms Following Immune Effector Cell-Associated Neurotoxicity Syndrome in Patients With Large B-cell Lymphoma Treated With Chimeric Antigen Receptor-Modified T Cell Therapy , Transplant Cell Ther, 00912-1.(25): 2025,S2666-6367

Landsburg, DJ Improving Cure Rates for Patients with Newly Diagnosed Large B-Cell Lymphomas: Targeted Therapies for High-Risk Pathologic Subgroups as Defined by Clinical Laboratory Testing , Cancers (Basel), 17(1): 2024,18

Landsburg DJ, Morrissette JJD, Nasta SD, Barta SK, Schuster SJ, Chong EA, Svoboda J, Barlev A, Bagg A, Priore SF. Genomic features of newly diagnosed large B cell lymphoma with or without subsequent disease progression , Cancer Res Commun, 4(11): 2024,2947-2954

Ni V, Nasta SD, Barta SK, Schuster SJ, Chong EA, Svoboda J, Morrissette JJD, Barlev A, Bagg A, Priore SF, Landsburg DJ. Identification of a clinicopathologic prognostic index for newly diagnosed large B cell lymphoma patients treated with R-CHOP , Haematologica, 110(4): 2024,1023-1027

Schneider, Michael, Landsburg, Daniel The role of pathologic testing in the diagnosis and management of patients with diffuse large B cell lymphoma: a narrative review , Annals of Lymphoma, 8: 2024,doi: 10.21037/aol-23-19

Landsburg DJ, Morrissette JJ, Nasta SD, Barta SK, Schuster SJ, Svoboda J, Chong EA, Bagg A. TP53 mutations predict for poor outcomes in patients with newly-diagnosed aggressive B cell lymphomas in the current era , Blood Adv, 7(23): 2023,7243-7253